Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
about
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosisCryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortalityInvasive pulmonary aspergillosis in patients with decompensated cirrhosis: case seriesAspergillus infections in transplant recipients.Targeted versus universal antifungal prophylaxis among liver transplant recipientsFungal infections: their diagnosis and treatment in transplant recipients.Fungal infections in solid organ transplantation.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Invasive fungal infections and antifungal therapies in solid organ transplant recipients.Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?Cryptococcosis in solid organ transplant recipients: current state of the scienceDiagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients.Cryptococcal Infection in Transplant Kidney Manifesting as Chronic Allograft Dysfunction.Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients.Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases.In vitro susceptibility of Candida isolates from organ transplant recipients to newer antifungals.Aspergillosis in solid organ transplantation.Invasive candidiasis following liver transplantation and surgical complications.Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.[Invasive fungal infections in patients after liver transplantation][Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole].Antifungal management practices in liver transplant recipients.Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study.Aspergillosis in children after liver transplantation: Single center experience.Pattern of bacterial and fungal infections in the first 3 months after pediatric living donor liver transplantation: an 11-year single-center experience.Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007).Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety.Risk Factors for Invasive Aspergillosis in Solid-Organ Transplant Recipients: A Case-Control StudyManagement of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions
P2860
Q30433949-191F1941-8809-4469-88C6-B33DD63B2A57Q30438524-1073AFD3-9A5D-4B21-AA9B-590417588B35Q33271183-E6816D54-24AA-4EA2-840B-41B3222069ECQ33719294-B6B322D7-6EF7-4050-A8EA-2758F43AB715Q35194743-F6EA5252-6B6D-4671-B69C-552EE0BE439EQ36206568-72E80AF7-5960-4547-8F4E-33FFCC238280Q36382578-E03576FF-235F-4153-84F3-ECBBF5E005DBQ36868273-941693E5-611C-49C9-A49C-781EFEF3FA3FQ36872848-ED707DCA-3FC1-465D-9FFF-8AE867EA5744Q37098160-021BD447-CE02-464F-A961-7AEBF3574597Q37226750-8EE78E8B-E60F-4E49-9FB5-C9516EB4BA99Q37650317-59621585-7BF2-498D-985B-EBAFF0945671Q40047755-3D4640D8-0D86-4EDD-A7FC-A2902C75F610Q40855547-A7A09FDA-29D1-45C8-BDA0-00B4756F3C10Q41673871-0F3182AB-DA73-432C-9EF9-CFEAA4B392C9Q41687666-8C705043-BEF9-4289-8445-D4EDDF4A1B25Q42221406-CB75E8F1-F578-4CD3-ADCF-17F02E5B579AQ42272291-45EE87B6-7CC5-48E2-8029-00C1AC1D424BQ44077309-D1D63F52-2C25-4E4E-B204-C80B96D3C276Q46284853-CEAFA294-18CC-4F15-B3EC-8D90CAF3D96CQ46434488-501E71BE-8527-42BC-BB8F-75364A19EF25Q46434492-76D3B784-5790-4ED7-9C38-3E277D5775F1Q46812014-B54C5C99-4C15-450E-BA35-2C73AD8493A2Q46877345-C44787DB-C28D-440A-95B2-8F3B9D022B71Q46903637-0EE782A7-07E4-4950-9224-C91A3824E427Q46919941-488E0384-EEC5-43FE-85EE-5FC448B6DF2BQ51019320-6B5D6FBB-1EAE-4D45-B809-0C771024B050Q51172313-65995AA5-9C59-4E32-A680-410A7B7F314EQ53159378-0CE20EAB-E34C-4CD9-813F-B52A85694AA1Q57569335-D79337E8-8514-4842-8089-3A9FE66FF099Q57815117-CA7D2CA1-5957-453B-8AD1-0F017D2E1A2E
P2860
Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Prevention of invasive fungal ...... ricin B in high-risk patients.
@en
Prevention of invasive fungal ...... ricin B in high-risk patients.
@nl
type
label
Prevention of invasive fungal ...... ricin B in high-risk patients.
@en
Prevention of invasive fungal ...... ricin B in high-risk patients.
@nl
prefLabel
Prevention of invasive fungal ...... ricin B in high-risk patients.
@en
Prevention of invasive fungal ...... ricin B in high-risk patients.
@nl
P2093
P356
P1476
Prevention of invasive fungal ...... ricin B in high-risk patients.
@en
P2093
Alberto Honrubia
Angel Candela
Emilio de Vicente
Javier Nuño
Jesus Fortún
Maria Uriarte
Miguel García
Pilar Martín-Davila
Rafael Barcena
Santiago Moreno
P304
P356
10.1093/JAC/DKG450
P407
P577
2003-10-16T00:00:00Z